Which is Better: Mounjaro or Wegovy for Weight Loss?

Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Two medications have transformed weight loss therapy in recent years: tirzepatide (Mounjaro) and semaglutide (Wegovy). While both belong to the GLP-1 receptor agonist class, they activate different peptide pathways and produce measurably different results in clinical trials. PlexusDx provides access to compounded versions of both medications, allowing patients to find the right fit for their metabolic profile.

How Tirzepatide and Semaglutide Work Differently

Semaglutide activates the GLP-1 receptor, which controls appetite signals in the brain and slows stomach emptying. Tirzepatide performs dual action by stimulating both GLP-1 and GIP receptors simultaneously. This dual activation targets two separate appetite-control pathways rather than one, which explains why some patients see greater weight reduction with tirzepatide in head-to-head comparisons.

The SURMOUNT-1 trial demonstrated that tirzepatide produced average weight losses of 22.5% of body weight at the highest dose, compared to semaglutide's 17.4% weight loss in the STEP trials. However, individual response varies significantly based on genetic factors, metabolism, and lifestyle. Some patients respond better to single-pathway activation, while others benefit from the dual mechanism tirzepatide offers.

Clinical Trial Results: Weight Loss Comparison

The SURMOUNT trials established tirzepatide's efficacy across multiple dose levels, with participants losing 16-22% of baseline body weight depending on the dose administered. Semaglutide's STEP program showed 10-18% weight loss across its trial population. Both medications significantly outperform lifestyle modification alone, but tirzepatide's dual receptor activation generally produced larger reductions in clinical settings.

Beyond weight loss, both medications improve cardiometabolic markers including blood pressure, triglycerides, and fasting glucose. Tirzepatide demonstrated slightly greater improvements in some lipid profiles and insulin sensitivity measures. Trial participants on both medications reported sustained appetite reduction and improved satiety, though onset speed and plateau timing differ between individuals and between the two drugs.

Side Effects and Tolerability: What Patients Experience

Nausea, vomiting, and gastrointestinal upset represent the most common side effects for both medications, typically occurring during dose escalation phases. Tirzepatide trials reported nausea in approximately 25-40% of participants, with severe nausea in 5-10% of cases. Semaglutide shows a similar side effect profile, though some patients report faster GI adaptation with semaglutide alone compared to the dual-pathway tirzepatide approach.

Dehydration risk increases with both medications due to nausea and reduced food intake, making adequate fluid consumption essential. Rare but serious pancreatitis has been reported with both drug classes, though causality remains unclear. Most side effects resolve within the first 4-8 weeks as the body adjusts, and dose escalation timing significantly influences symptom severity. PlexusDx patients work with clinical teams to manage side effects through titration adjustments and supportive care strategies.

Choosing Your Medication: Tirzepatide vs Semaglutide at PlexusDx

PlexusDx offers compounded tirzepatide injection at $289/mo month-to-month, or from $249/mo on the 6-month plan, with no price increases as dose escalates—a pricing model that reflects PlexusDx's commitment to accessible precision care. Compounded semaglutide injection is $189/mo month-to-month, or from $149/mo on the 6-month plan, providing a lower entry point for patients starting GLP-1 therapy. Both medications are sourced from licensed 503A compounding pharmacies and serve all 50 states without insurance requirements.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide more effective than semaglutide for weight loss?

Clinical trials show tirzepatide typically produces greater average weight loss (22.5% vs 17.4% in comparable studies), primarily due to its dual GLP-1 and GIP receptor activation. However, individual results vary significantly, and some patients achieve their goals equally well with semaglutide alone. Your genetic profile and metabolic factors influence which medication suits you better.

Can I switch from Wegovy to Mounjaro or vice versa?

Yes, patients can transition between these medications under clinical supervision. Switching typically involves stopping one medication for a brief washout period, then starting the alternative at a low dose. PlexusDx clinicians can guide this transition safely and monitor your response to the new medication.

How much does tirzepatide cost compared to semaglutide at PlexusDx?

PlexusDx compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan), while compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan). Your dose may increase during treatment, but your monthly price stays flat—it won't rise with dose adjustments. Both are HSA/FSA eligible and available nationwide without insurance.

What does the Precision Peptide Genetic Test tell me about these medications?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Are compounded tirzepatide and semaglutide as safe as brand-name versions?

PlexusDx sources all medications from licensed 503A compounding pharmacies, which follow strict FDA manufacturing standards and quality controls. While compounded medications aren't FDA-approved, they meet rigorous pharmaceutical safety protocols. Your PlexusDx clinician monitors your health throughout treatment to ensure safety and efficacy.

Related Reading

• Wegovy For Weight Loss 2
• Mounjaro For Weight Loss 2
• Wegovy Weight Loss Pills
• Weight Loss Mounjaro

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.